Significance of systemic endotoxaemia in inflammatory bowel disease

Gut

Volumn 36, Issue 6, 1995, Pages 897-901

  Gardiner, K R ^a   Halliday, M I ^a   Barclay, G R ^b   Milne, L ^b   Brown, D ^c   Stephens, S ^c   Maxwell, R J ^a   Rowlands, B J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b Blood Transfusion Centre   (United Kingdom)

^c UCB PHARMA   (Belgium)

Author keywords

Endotoxaemia; Inflammatory bowel disease

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; ENDOTOXIN; IMMUNOGLOBULIN G; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; ENDOTOXEMIA; ENTERITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0029010945     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.36.6.897     Document Type: Article

References (35)

1. Tytgat GNJ, Mulder CJJ. The aetiology of Crohn's disease. Int J Colorectal Dis 1986; 1: 188-92.
2. Parent K, Mitchell P. Cell wall-defective variants of pseudomonas-like (Group Va) bacteria in Crohn's disease. Gastroenterology 1978; 75: 368-72.
3. Kobayashi K, Blaser MJ, Brown WR. Immunohistochemical examination for mycobacteria in intestinal tissues from patients with Crohn's disease. Gastroenterology 1987; 92: 436-42.
4. Matthews N, Mayberry JF, Rhodes J, Neale L, Munro J, Wensinck F. Agglutinins to bacteria in Crohn's disease. Gut 1980; 21: 376-80.
5. Aoki K. A study of endotoxaemia in ulcerative colitis and Crohn's disease. I. Clinical study. Acta Med Okayama 1978; 32: 147-58.
6. Sartor RB, Bond TM, Schwab JH. Systemic uptake and intestinal effects of luminal bacterial cell wall polymers in rats with acute colonic injury. Infect Immun 1988; 56: 2101-8.
7. LeDuc LE, Nast CC. Chemotactic peptide-induced acute colitis in rabbits. Gastroenterology 1990; 98: 929-35.
8. Hotta T, Yoshida N, Yoshikawa T, Sugino S, Kondo M. Lipopolysaccharide-induced colitis in rabbits. Res Exp Med 1986; 186: 61-9.
9. Sartor RB, Cromartie WJ, Powell DW, Schwab JH. Granulomatous enterocolitis induced in rats by purified bacterial cell wall fragments. Gastroenterology 1985; 89: 587-95.
10. Colin R, Grancher T, Lemeland J-F, Hecketsweiler P, Galmiche JP, Le Grix A. Recherche d'une endotoxinemie dans les entero-colites inflammatoires cryptogenetiques. Gastroenterol Clin Biol 1979; 3: 15-9.
11. Wellmann W, Fink PC, Benner F, Schmidt FW. Endotoxaemia in active Crohn's disease. Treatment with whole gut irrigation and 5-aminosalicylic acid. Gut 1986; 27: 814-20.
12. Sturk A, van Deventer SJH, Wortel CH, Levels JH, ten Gate JW, Büller HR. Detection and clinical relevance of human endotoxaemia. Z Med Lab Diagn 1990; 31: 147-58.
13. Walker RI, Porvaznik MJ. Disruption of the permeability barrier (Zonula Occludens) between intestinal epithelial cells by lethal doses of endotoxin. Infect Immun 1978; 21: 655-8.
14. O'Dwyer ST, Michie HR, Ziegler TR, Revhaug A, Smith RJ, Wilmore DW. A single dose of endotoxin increases intestinal permeability in healthy humans. Arch Surg 1988;123:1459-64.
15. Barclay GR, Scott BB. Serological relationships between Escherichia coli and Salmonella smooth- and roughmutant lipopolysaccharides as revealed by enzyme-linked immunosorbent assay for human immunoglobulin G antiendotoxin antibodies. Infect Immun 1987; 55: 2706-14.
16. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316: 379-85.
17. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. BMJ 1955; 2: 1041-8.
18. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancer 1980; i: 514.
19. Engelberts J, Moller A, Schoen GJM, van der Linden CJ. Evaluation of the measurement of human TNF in plasma by ELISA. Lymphokine Cytokine Res 1991; 10: 69-74.
20. Cooke WT, Prior P. Determining disease activity in inflammatory bowel disease. J Clin Gastroenterol 1984; 6: 17-25.
21. van Deventer SJH, Buller HR, ten Gate JW, Sturk A, Pauw W. Endotoxaemia: an early predictor of septicaemia in febrile patients. Lancet 1988; i: 605-9.
22. Fink PC, Lehr L, Urbaschek RM, Zozak J. Limulus amoebocyte lysate test for endotoxemia: investigations with a femtogram sensitive spectrophotometric assay. Klin Wochenschr 1981; 59: 213-8.
23. Magliulo E, Scevola D, Fumarola D. Limulus test in Escherichia coli enteritis. Lancet 1975; i: 407.
24. Fossard DP, Kakkar W. The limulus test in experimental and clinical endotoxaemia. Br J Surg 1974; 61: 798-804.
25. MacDonald TT, Hutchings P, Choy M-Y, Murch S, Cooke A. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990; 81: 301-5.
26. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor α in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913-7.
27. Chikanza IC, Roux-Lombard P, Dayer J-M, Panayi GS. Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin Exp Immunol 1993; 92: 19-22.
28. Foley N, Lambert C, McNicol M, Johnson N, Rook GAW. An inhibitor of the toxicity of tumour necrosis factor in the serum of patients with sarcoidosis, tuberculosis and Crohn's disease. Clin Exp Immunol 1990; 80: 395-9.
29. van Deventer SJH, Jansen J, van der Poll T, Godfried M, ten Gate JW. Soluble TNF receptors as a disease severity marker in inflammatory and infectious diseases. [Abstract]. In: Proceedings of the International Conference on Endotoxins. Amsterdam: August, 1993: 19.
30. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha as a marker of intestinal inflammation. Lancet 1992; 339: 89-91.
31. Mahida YR, Wu K, Lamming CED, Jewell DP, Hawkey CJ. Human colonic tumour necrosis factor-a (TNFa) production. Gastroenterology 1989; 96: A313.
32. Mazlam MZ, Hodgson HJF. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut 1992; 33: 773-8.
33. Warshaw AL, Bellini CA, Walker WA. The intestinal mucosal barrier to intact antigenic protein. Difference between colon and small intestine. Am J Surg 1977; 13: 55-8.
34. 51Cr-EDTA in patients with gastrointestinal inflammatory disease. Am J Gastroenterol 1987; 82: 1159-64.
35. Wensinck F, Custers-van Lieshout LMC, Poppelaars-Kustermans PAJ, Schröder AM. The faecal flora of patients with Crohn's disease. J Hyg 1981; 87: 1-12.